FDA approves first targeted therapy for metastatic bladder cancer
The FDA granted accelerated approval to Balversa (erdafitinib), a treatment for adult patients with locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following prior platinum-containing chemotherapy.
Source: Food and Drug Administration - Category: American Health Source Type: news
More News: American Health | Bladder Cancer | Cancer | Cancer & Oncology | Chemotherapy | Food and Drug Administration (FDA) | Genetics